Title of Invention

A METHOD FOR IMPROVING THE RADIOSTABILITY OF A 18F-FLUOR-DEOXY-GLUCOSE (18F-FDG)-SOLUTION

Abstract

The invention relates to a method for improving the radio stability of a <sup>18</sup> F-fluor-deoxy-glucose (<sup>18</sup> p-FDG)-solution during autoclaving, which method comprises the steps of a) provision of a <sup>18</sup> F-fluor-deoXY-glucose (<sup>18</sup> p-FDG)-solution, and b) addition of at least one buffer based on a weak acid to the <sup>18</sup> F-fluor-deoxy- glucose (<sup>18</sup> F-FDG)-solution, wherein said at least one buffer is selected from the group consisting of a citrate buffer with a pH lower than 5.5, an acetate buffer, an ascorbate .buffer and combinations thereof.

Full Text

METHOD FOR OBTAINING A 2-18P-FLUOR-2-DEOXY-D-GLUCOSB (18F-FDG)-SOLUTION The present invention relates to a method for obtaining a 2- [18F]fluor-2-deoxy-D-glucose (also described herein as 18F-fluor-deoxy-glucose or 18F-FDG)-solution with improved physical/chemical characteristics, i.e. lOradiochemical stability, and a (sterile) 18F-FDG-solution thus obtained. In recent years, in the field of Nuclear Medicine, the compound 18F-FDG, aside from important uses in cardiology and neurology, has shown an ability to detect cancerous 15tissues undetectable by conventional means or to correct misdiagnosis of the disease. This is due to exploiting a fundamental change that occurs in cells when they become malignant; cancer cells lose their ability to efficiently convert glucose into energy. Consequently, they require much 20more glucose, up to 20 to 50 times more. 18F-FDG is usually prepared with the help of a fully automated synthesizer. Because the compound needs to be injected in patients, it is required that the solution containing the compound is sterilized prior to injection. 25However, the radiochemical purity of the compound decreases drastically during standard autoclaving steps and thus the compound fails to meet the specifications dictated by the European and United States Pharmacopeia. In addition, after synthesis, 18F-FDG rapidly loses in radiochemical purity due 30to both radiolysis and the half-life of the radioisotope, limiting the period in which the compound can be used. It is the object of the present invention to provide a 18F-fluor-deoxy~glucose (FDG)-solution which can be autoclaved while still meeting the specification of more than 95% radiochemical purity eight hours after production. In iaddition, it is the object of the present invention to reduce, after synthesis, the effect of radiolysis of 18F-FDG in solution. In the research leading to the present invention, it has been found that buffering the 18F-FDG-solution has a 3strong effect on the physical/chemical characteristics, i.e. the radiostability. It has been surprisingly found that buffers based on a weak acid improve the physical/chemical characteristics, i.e. the radiostability, of a 18F-FDG-solution to such extent that it becomes possible to autoclave 5this solution and maintain a radiochemical purity of at least 95%. This is achieved according to the invention by a •method comprising the following steps: a) provision of a 18F-fluor-deoxy-glucose (18F-FDG)-solution, and b) addition of at least one buffer based on a weak acid to the 18F-FDG-solution. The weak acid buffer should be physiologically acceptable and is preferably a citrate buffer, an acetate buffer, an >5ascorbate buffer or a combination of these buffers. The improved physical/chemical characteristics of the 18F-FDG-solution are obtained when the pH of the citrate buffer is lower than 5.5, in particular between 2 and 5.5. For the acetate buffer, these characteristics are obtained at 30pH values between 3.0 and 5.5. The ascorbate buffer is used in a similar pH range as the acetate buffer between 3.0 and 5.5. Autoclaving of the F-FDG-solution is performed at a temperature between 110EC and 150EC, preferably at a temperature between 130EC en 140EC and more preferably at a temperature of 134EC. It was found that these temperatures 5are optimal considering stability and half-life of the 18F radio-isotope. The autoclaving process of the 18F-FDG-solution is performed during 1 to 30 minutes, preferably during 1 to 10 minutes and more preferably during 2 to 5 minutes- These ranges have been optimized considering the lOrelatively short half-life of the 18F radio-isotope, which is 109.8 minutes. The present invention will be further elucidated in the examples that follow and which are given for illustration purposes only and are not limiting the scope of the 15invention. EXAMPLES EXAMPLE 1 Autoclaving of a 18F-FDG-solution at pH range 4.5 to 5.5 20 In this example, three test runs have been performed to study the radiochemical purity of a 18F-fluor-deoxy-glucose (FDG)-solution buffered with a weak acid as compared to the non-buffered solution in saline. Directly after production, the 18F-f luor-deoxy-25glucose (FDG)-solution is diluted with saline to a radioactive concentration of 3 mCi/ml at ART (Activity Reference Time) (t=0). Two hours after production, vials with 0.5 ml of 18F-fluor-deoxy-glucose (FDG)-solution were prepared, mixed with 0.1 ml of buffer (10 mM) and then 30autoclaved. Table 1 illustrates the radiochemical purity of the differently buffered 18F-fluor-deoxy-glucose (FDG)-solutions after autoclaving during 5 minutes at 134°C. Measurements were carried out directly after autoclaving using a KAVO Sterimaster™. All the buffers tested gave a higher radiochemical lOpurity than the non-buffered reference sample NaCl/pH 6.2. The buffer giving the best results is the citrate buffer with a pH of 4.5. As compared to the not autoclaved samples, only one out of three experiments showed a decrease in the radiochemical purity of 1% (test 1). Example 2 Autoclaving 18F-FDG-solution at low pH-ranges (pH 2-3) In this example, two test runs have been performed . 5to study the radiochemical purity of a 18F-fluor-deoxy-glucose (FDG)-solution buffered with a weak acid to pH 2-3. Directly after production, the 18F-f luor-deoxy-glucose (FDG)-solution is diluted with saline to a radioactive concentration of 3 mCi/ml at ART (12:00 h)- Two lOhours after production, vials with 0.5 ml of 18F-fluor-deoxy-glucose (FDG)-solution were prepared, mixed with 0.1 ml of buffer (100 mM) and then autoclaved Table 2 illustrates the radiochemical purity of the differently buffered 18F-fluor-deoxy-glucose (FDG)-solutions 15after autoclaving during 5 minutes at 134°C. All three buffers tested yielded a higher radiochemical purity than the non-buffered reference sample NaCl/pH 6.2. Compared to the reference sample (decrease in radiochemical purity 9%) only a 2-3% decrease in radiochemical purity was observed for the samples buffered with a weak acid. For all buffers (ascorbate, citrate and acetate), no significant decrease in the radiochemical purity 5was measured as compared to the non-autoclaved samples (Table 1). EXAMPLE 3 Radiolysis of 18F~FDG 10 The radiolysis of 18F-FDG was measured during a period of approximately 8.5 hours. The radioactive concentration was 3 mCi/ml at ART (t=0). Two buffers were tested and compared to the reference sample in 0.9% NaCl/pH 6.9. The first buffer was a 15citrate buffer pH 4.5 and the second buffer an ascorbate buffer pH 4.5. Five determinations of the radiochemical purity of the samples were conducted during the interval. The results are illustrated in table 3. compared to the 0.9% NaCl sample. The largest decrease in radiolysis was observed when using the ascorbate buffer. Only a 2% decrease in activity was observed after 8.5 hours. This 5decrease was 4% and 6% for the citrate buffer and the 0.9% NaCl, respectively. In conclusion, 18F-FDG is more stable after addition of an ascorbate or citrate buffer than without the addition of these buffers. 10 EXAMPLE 4 Autoclaving and radiolysis of 18F-fluor-deoxy-glucose (FDG)-solutions The radiolysis of 18F-FDG was measured during a period of approximately 7.5 hours after autoclaving the 15sample. Two buffers were tested and compared to the reference sample in 0.9% NaCl/pH 6.9. The first was a citrate buffer pH 4.5 and the second an ascorbate buffer pH 4.5. Three determinations of the radiochemical purity of the samples were conducted during the interval. The results are illustrated in table 4, stable under autoclavation conditions. Without addition of this' buffer, the radiochemical purity of the sample drops lOdramatically to less than 90%. A citrate buffer yields better stability of the 18F-FDG-solution as compared to ascorbate. In addition, radiolysis, after autoclaving, in both buffers tested was decreased as compared to the NaCl sample. The largest decrease in radiolysis was observed when the ISascorbate buffer was used. Only a 1% decrease in activity was observed after 7.5 hours. This decrease was 2% and 3% for the citrate buffer and the NaCl sample, respectively. In conclusion, the i8F-FDG-solution is more stable after addition of an ascorbate or citrate buffer than without the 20presence of these buffers during autoclavation. After autoclaving, in both buffers the radiolysis of the 18F-FDG-solution was reduced. CLAIMS A method for improving one or more physical/chemical . characteristics of a 18F-fluor-deoxy-glucose (18F-FDG)-solution, which method comprises the steps of: a) provision of a 18F-fluor-deoxy-glucose (18F-FDG)-solution, and b) addition of at least one buffer based on a weak acid to the 18F-f luor-deoxy-glucose (18F-FDG)-solution. The method according to claim 1, wherein the improved physical/chemical characteristic is the ability of the 18F-FDG-solution to be autoclaved, thus rendering the solution suitable for medical applications. The method according to claim 1, wherein the improved physical /chemical Characteristic is reduced radiolysis in the 18F-fluor-deoxy-glucose (FDG)-solution. The method according to claim 1, wherein the buffer based on a weak acid, is selected from the group consisting of citrate, acetate, ascorbate and combinations thereof. The method according to claim 4, wherein the pH of the citrate buffer is lower than 5.5, preferably between pH 2 and 5.5. The method according to claim 4, wherein the pH of the acetate buffer is between 3.0 and 5.5. The method according to claim 4, wherein the pH of the ascorbate buffer is between 3.0 and 5.5. A method of preparing a sterile 18F-fluor-deoxy-glucose (18F-FDG)-solution by autoclaving a 18F-fluor-deoxy-glucose (FDG)-solution at a temperature between 110°C and 145°C. A method of preparing a sterile 18F-fluor-deoxy-glucose (18F-FDG)-solution by autoclaving a 18F-fluor-deoxy-glucose (FDG)-solution at a temperature between 130°C and 140°C. A method of preparing a sterile 18F-fluor-deoxy-glucose (18F-FDG)-solution by autoclaving a 18F-f luor-deoxy-glucose (FDG)-solution at a temperature of 134°C. The method acording to claim 8, wherein the autoclaving process is performed for a period of 1 to 30 minutes. The method according to claim 8, wherein the autoclaving process is performed for a period of 1 to 10 minutes. The method according to claim 8, wherein the autoclaving process is performed for a period of 2 to 5 minutes. A 18F-fluor-deoxy-glucose (FDG)—solution with improved physical/chemical characteristics obtained by the method of claim 1. A sterile fludeoxyglucose (FDG)-solution obtained by the method of claim 8. 16. A method for improving one or more physical/chemical characteristics substantially as herein described and exemplified.

Documents:

2387-chenp-2004 claims granted.pdf

2387-chenp-2004 description (complete) granted.pdf

2387-chenp-2004-claims.pdf

2387-chenp-2004-correspondnece-others.pdf

2387-chenp-2004-correspondnece-po.pdf

2387-chenp-2004-description(complete).pdf

2387-chenp-2004-form 1.pdf

2387-chenp-2004-form 3.pdf

2387-chenp-2004-form 5.pdf

2387-chenp-2004-from 18.pdf

2387-chenp-2004-pct.pdf